Vice Provost and Dean of Research
Showing 61-70 of 2,415 Results
-
Kevin Arrigo
Donald and Donald M. Steel Professor of Earth Sciences and Senior Fellow at the Woods Institute for the Environment
Current Research and Scholarly InterestsInvestigates role of ocean biology in gobal carbon and nutrient cycles.
-
Steven Artandi, MD, PhD
Laurie Kraus Lacob Director of the Stanford Cancer Institute (SCI), Jerome and Daisy Low Gilbert Professor and Professor of Biochemistry
Current Research and Scholarly InterestsTelomeres are nucleoprotein complexes that protect chromosome ends and shorten with cell division and aging. We are interested in how telomere shortening influences cancer, stem cell function, aging and human disease. Telomerase is a reverse transcriptase that synthesizes telomere repeats and is expressed in stem cells and in cancer. We have found that telomerase also regulates stem cells and we are pursuing the function of telomerase through diverse genetic and biochemical approaches.
-
Ann M. Arvin
Lucile Salter Packard Professor of Pediatrics and Professor of Microbiology and Immunology, Emerita
Current Research and Scholarly InterestsOur laboratory investigates the pathogenesis of varicella zoster virus (VZV) infection, focusing on the functional roles of particular viral gene products in pathogenesis and virus-cell interactions in differentiated human cells in humans and in Scid-hu mouse models of VZV cell tropisms in vivo, and the immunobiology of VZV infections.
-
Itai Ashlagi
Professor of Management Science and Engineering, Senior Fellow at the Stanford Institute for Economic Policy Research and, Professor, by courtesy, of Economics
BioItai Ashlagi is a Professor at the Management Science & Engineering Department.
He is interested in game theory and the design and analysis of marketplaces. He is especially interested in marketplaces, in which matching is an essential activity. markets, for which he developed mechanisms using tools from operations/cs and economics. His work influenced the practice of Kidney exchange, for which he has become a Franz Edelman Laureate. Ashlagi received his PhD in operations research from the Technion-Israel Institute of Technology.
Before coming to Stanford he was an assistant professor of Operations Management at Sloan, MIT and prior to that a postdoctoral researcher at HBS. He is the recipient of the outstanding paper award in the ACM conference of Electronic Commerce 2009. His research is supported by the NSF including an NSF-CAREER award. -
Euan A. Ashley
Roger and Joelle Burnell Professor of Genomics and Precision Health, Arthur L. Bloomfield Professor of Medicine and Professor of Genetics, of Biomedical Data Science and, by courtesy, of Pathology
Current Research and Scholarly InterestsThe Ashley lab is focused on precision medicine. We develop methods for the interpretation of whole genome sequencing data to improve the diagnosis of genetic disease and to personalize the practice of medicine. At the wet bench, we take advantage of cell systems, transgenic models and microsurgical models of disease to prove causality in biological pathways and find targets for therapeutic development.
-
Themistocles (Tim) Assimes
Associate Professor of Medicine (Cardiovascular Medicine) and, by courtesy, of Epidemiology and Population Health
Current Research and Scholarly InterestsGenetic Epidemiology, Genetic Determinants of Complex Traits related to Cardiovasular Medicine, Coronary Artery Disease related pathway analyses and integrative genomics, Mendelian randomization studies, risk prediction for major adverse cardiovascular events, cardiovascular medicine related pharmacogenomics, ethnic differences in the determinants of Insulin Mediated Glucose Uptake, pharmacoepidemiology of cardiovascular drugs & outcomes
-
Laura Attardi
Catharine and Howard Avery Professor of the School of Medicine and Professor of Genetics
Current Research and Scholarly InterestsOur research is aimed at defining the pathways of p53-mediated apoptosis and tumor suppression, using a combination of biochemical, cell biological, and mouse genetic approaches. Our strategy is to start by generating hypotheses about p53 mechanisms of action using primary mouse embryo fibroblasts (MEFs), and then to test them using gene targeting technology in the mouse.
